Wir benötigen Ihre Einwilligung zur Verwendung der einzelnen Daten, damit Sie unter anderem Informationen zu Ihren Interessen einsehen können. Klicken Sie auf "OK", um Ihre Zustimmung zu erteilen.
Standard Practice for Real-time Release Testing of Pharmaceutical Water for the Total Organic Carbon Attribute
Automatische name übersetzung:
Standard Praxis für Echtzeit-Freigabetests der Pharmawasser für die Total Organic Carbon Attribut
NORM herausgegeben am 1.8.2010
Bezeichnung normen: ASTM E2656-10
Anmerkung: UNGÜLTIG
Ausgabedatum normen: 1.8.2010
SKU: NS-45819
Zahl der Seiten: 8
Gewicht ca.: 24 g (0.05 Pfund)
Land: Amerikanische technische Norm
Kategorie: Technische Normen ASTM
Keywords:
ICS Number Code 11.120.10 (Medicaments), 13.060.50 (Examination of water for chemical substances)
Significance and Use | ||||||||||||||||||
Pharmaceutical water is the most common component or ingredient used in pharmaceutical and biopharmaceutical manufacturing. Acceptable purity of the water is important to the quality of the final pharmaceutical product. TOC concentration is a key indicator and attribute of the purity of this water and also an important monitor of the overall performance of the water purification system. TOC analysis is the measurement of all the covalently bound carbon present in the water, not including carbon in the form of carbon dioxide (CO2), bicarbonate icon (HCO3–), or carbonate ion (CO32–), and is reported as the mass of organic carbon per volume. Application of this practice provides pertinent information to make informed decisions on the release of water meeting pharmaceutical TOC concentration specifications. |
||||||||||||||||||
1. Scope | ||||||||||||||||||
1.1 This practice establishes an approach to the real-time release testing (RTRT) of pharmaceutical water based on the total organic carbon (TOC) attribute using on-line total organic carbon (OLTOC) instrumentation that is in agreement with current regulatory thinking. 1.2 This practice is harmonized with or supports the concepts of relevant ASTM International Committee E55 on Manufacture of Pharmaceutical Products standards, ICH Harmonized Tripartite Guidelines, the US FDA PAT Guidance, and US FDA Pharmaceutical cGMPs. 1.3 This practice does not provide general guidance information for pharmaceutical procedures that are considered standard practice in the pharmaceutical industry. This practice provides specific guidance for non-standardized procedures. 1.4 This practice does not address the user’s various internal procedures for risk, change, or quality management systems. The overall project effort associated with this practice shall be proportional to the overall risk of failing the pharmaceutical water’s TOC concentration specification. 1.5 This practice does not purport to establish how to comply with pharmacopeias. The RTRT methodology selected must assure compliance with the user’s current required pharmacopeias. However, compliance with pharmacopeia TOC methods is not necessarily sufficient to meet current regulatory expectations for RTRT. 1.6 This practice does not purport to substitute for or replace compendial bioburden testing requirements. It is strictly applicable to the TOC attribute of water quality. 1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use. |
||||||||||||||||||
2. Referenced Documents | ||||||||||||||||||
|
Historisch
1.4.2014
Historisch
15.12.2010
Historisch
15.5.2009
Historisch
1.6.2011
Historisch
1.8.2013
Historisch
1.2.2008
Wollen Sie sich sicher sein, dass Sie nur die gültigen technischen Vorschriften verwenden?
Wir bieten Ihnen Lösungen, damit Sie immer nur die gültigen (aktuellen) legislativen Vorschriften verwenden könnten.
Brauchen Sie mehr Informationen? Sehen Sie sich diese Seite an.
Letzte Aktualisierung: 2024-12-22 (Zahl der Positionen: 2 217 000)
© Copyright 2024 NORMSERVIS s.r.o.